Churg and Naso have recently hypothesized that the use of only two immunostains usually could enable the highly accurate differentiation between epithelioid/biphasic mesotheliomas from NSCLC carcinomas using HEG1 and Claudin-4 IHC labelling in combination (12). The gene discussed is CLDN4; the disease is carcinoma.